Insuficiencia renal y resistencia insulínica: efecto de la dosis de diálisis

Mínguez, Clarisa González; López-Suárez, A.; Soto, Marı́a José; Ceballos, M; Bailén, María; Benítez, Encarnación; Girón-González, José A.

doi:10.1157/13109833

Cited by 2 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results obtained indicate that replacement therapy, by reducing the disturbances associated with advanced renal failure, can reduce IR, which is consistent with the work by Kabayashi et al [ 10 ]. Beneficial effects of renal replacement therapy in order to reduce IR are confirmed by the work of Minguez et al, who found that HOMA-IR in HDpts showed a negative correlation with Kt/V marker demonstrating the adequacy of dialysis [ 15 ]. Trirogoff et al assessed IR using HOMA-IR in patients with stages 3 and 4 of CKD, finding no significant differences compared with the control group [ 16 ].…”

Section: Discussionmentioning

confidence: 97%

Visceral Adipose Tissue is Associated with Insulin Resistance in Hemodialyzed Patients

Giers

Niemczyk

Szamotulska³

et al. 2015

Med Sci Monit

View full text Add to dashboard Cite

BackgroundIt has not been definitively established which factors affect insulin resistance (IR) and whether dialysis decreases IR. The aim of this study was to investigate factors that may have an influence on homeostasis model assessment (HOMA-IR) in hemodialyzed patients (HDpts) and to compare IR between HDpts and healthy subjects.Material/MethodsWe examined 33 HDpts and paired 33 subjects of the control group, matched for sex, age, and BMI. We analyzed concentrations of insulin, glucose, leptin, resistin, and total and high-molecular-weight adiponectin (HMWad) in serum. Using computed tomography in HDpts, we evaluated visceral adipose tissue (VAT), concentrations of visfatin, CRP, and IL-6.ResultsHOMA-IR (median, 1.3 vs. 1.4, P=0.19), insulin (median 6.8 vs. 6.0 μIU/mL, P=0.7), glucose (79 mg/dL vs. 93 mg/dL, P=0.001). IR in HDpts is dependent on VAT (r=0.36, P=0.04) and this relationship is stronger than the relationship of BMI and IR (r=0.3, P=0.1). In HDpts we found higher concentrations of leptin (P=0.001) and resistin (P<0.001), with no relation to IR. HMWad and its percentage in relation to total adiponectin are higher in HDpts (P=0.03 and P<0.001, respectively).ConclusionsHOMA-IR in HDpts does not differ from the control group. In HDpts it depends on the quantity of VAT and this relationship is stronger than with BMI. In HDpts leptin and resistin do not influence IR. HMWad and its percentage in total adiponectin are significantly higher in HDpts.

show abstract

Section: Discussionmentioning

confidence: 97%

Visceral Adipose Tissue is Associated with Insulin Resistance in Hemodialyzed Patients

Giers

Niemczyk

Szamotulska³

et al. 2015

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“…Defronzo et al showed that dialysis of renal patients thrice weekly for 10 weeks normalizes IR. This improvement is correlated with the dialysis dose [61]. Similarly, peritoneal dialysis is as efficient as HD as regard to IR [22].…”

Section: Dialysismentioning

confidence: 88%

Evidence to Support a Putative Role for Insulin Resistance in Chronic Kidney Disease

Shehab-Eldin¹,

Ragheb²,

Gazarin³

et al. 2010

Arab J. Nephr. Trans

View full text Add to dashboard Cite

Introduction: The primary cause of morbidity and mortality in the renal patient is a cardiovascular event. Insulin resistance (IR) contributes to this event by increasing cardiovascular disease (CVD) and accelerating rates of decline in kidney function. Here we review the historical background of IR in patients with chronic kidney disease (CKD) and present evidence for a role of IR in accelerating cardiovascular and renal diseases. Review: The high prevalence of IR in CKD patients is well documented. It is suggested that increased IR in the renal patient is caused by uremia as well as by other known factors in the general population. Patients with CKD have an alarmingly high risk for cardiovascular morbidity and mortality. There is overwhelming evidence to support a role for IR in increased CVD morbidity and mortality in the general population, which is likely to extend to CKD patients. Some of the traditional treatment measures for IR, such as metformin, may not be applicable to the renal patient. Other options include weight reduction, exercise, treatment of anemia to improve exercise tolerance, treatment of vitamin D deficiency, thiazolidinediones, and dialysis. IR is estimated by studying the relationship between blood glucose and the concomitant insulin level. Such measurement may help identify patients at increased risk for future cardiovascular events and guide treatment measures. Conclusion: Sufficient evidence supports the increased prevalence of IR in kidney patients. Treating IR may retard the progression of CKD and decrease the incidence of cardiovascular events in this high risk population.

show abstract

Insuficiencia renal y resistencia insulínica: efecto de la dosis de diálisis

Cited by 2 publications

References 22 publications

Visceral Adipose Tissue is Associated with Insulin Resistance in Hemodialyzed Patients

Visceral Adipose Tissue is Associated with Insulin Resistance in Hemodialyzed Patients

Evidence to Support a Putative Role for Insulin Resistance in Chronic Kidney Disease

Contact Info

Product

Resources

About